Zillow Group
Search documents
Zillow tops estimates with $654M in Q4 revenue, up 18%
GeekWire· 2026-02-10 22:14
Core Insights - Zillow continued to outperform investor expectations in the fourth quarter despite facing various court cases throughout the year [1] Company Performance - The company managed to exceed investor expectations in the fourth quarter, indicating strong operational performance [1]
Zillow Swings to Fourth-Quarter Profit as Revenue Climbs
WSJ· 2026-02-10 21:58
Core Insights - The home-listing site reported a quarterly profit of $3 million, a significant turnaround from a loss of $52 million in the same quarter of the previous year [1] Financial Performance - Quarterly profit: $3 million - Previous year's loss: $52 million - Year-over-year change: Profitability improved by $55 million [1]
Zillow Group(Z) - 2025 Q4 - Annual Results
2026-02-10 21:08
Reported Consolidated Results ZILLOW GROUP, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in millions, unaudited) | | | | December 31, | | | --- | --- | --- | --- | --- | | | | 2025 | | 2024 | | Assets | | | | | | Current assets: | | | | | | Cash and cash equivalents | $ | 768 | $ | 1,082 | | Short-term investments | | 527 | | 776 | | Accounts receivable, net | | 149 | | 104 | | Mortgage loans held for sale | | 386 | | 159 | | Prepaid expenses and other current assets | | 287 | | 210 | | Restricted cash | | 5 ...
Zillow Group(ZG) - 2025 Q4 - Annual Results
2026-02-10 21:08
Reported Consolidated Results ZILLOW GROUP, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in millions, unaudited) | | | | December 31, | | | --- | --- | --- | --- | --- | | | | 2025 | | 2024 | | Assets | | | | | | Current assets: | | | | | | Cash and cash equivalents | $ | 768 | $ | 1,082 | | Short-term investments | | 527 | | 776 | | Accounts receivable, net | | 149 | | 104 | | Mortgage loans held for sale | | 386 | | 159 | | Prepaid expenses and other current assets | | 287 | | 210 | | Restricted cash | | 5 ...
Zillow Group Reports Fourth-Quarter and Full-Year 2025 Financial Results
Prnewswire· 2026-02-10 21:05
Core Insights - Zillow Group reported strong financial results for Q4 and full-year 2025, achieving all full-year financial targets, including positive net income, while gaining market share in both For Sale and Rentals [1] - The company’s Q4 revenue increased by 18% year-over-year to $654 million, and full-year 2025 revenue rose by 16% to $2.6 billion, outperforming the residential real estate industry by significant margins [1][2] - Zillow's CEO highlighted the company's unique position to drive growth through innovative technology and a deeply engaged audience, celebrating 20 years of operation [1] Financial Performance - Q4 2025 For Sale revenue was $475 million, an 11% increase year-over-year, while Mortgages revenue surged by 39% to $57 million due to a 67% rise in purchase loan origination volume to $1.5 billion [1] - Residential revenue for Q4 2025 reached $418 million, up 8% year-over-year, benefiting from growth in agent and software offerings [1] - Adjusted EBITDA for Q4 was $149 million, representing a 33% increase from $112 million in Q4 2024, with an Adjusted EBITDA margin of 23% [1][3] Market Position - The residential real estate industry grew by 3% in Q4 and for the full year 2025, indicating Zillow outperformed the industry by 1,500 basis points in Q4 and 1,300 basis points for the full year [1] - Zillow's traffic to its apps and sites increased by 8% year-over-year to 221 million average monthly unique users, with visits up 2% to 2.1 billion [3] Non-GAAP Financial Measures - Adjusted net income for Q4 was $98 million, compared to $68 million in Q4 2024, with diluted adjusted net income per share rising to $0.39 from $0.27 [3] - Adjusted free cash flow for Q4 was $125 million, up from $78 million in Q4 2024, indicating strong cash generation capabilities [3][5]
Zillow Group (NasdaqGS:Z) Earnings Call Presentation
2026-02-10 21:00
February 2026 Zillow Investor Presentation Legal Disclosure This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties, including, without limitation, statements regarding our future targets, the future performance and operation of our business, our business strategies and ability to translate such strategies into financial performance, the current and future ...
Tech Investors Turn on Zillow. Why Wall Street Still Likes the Stock.
Barrons· 2026-02-10 08:00
Some analysts expect Zillow will have strong revenue growth as the housing market improves. ...
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
Prnewswire· 2026-02-05 13:30
Core Viewpoint - Atossa Therapeutics has reaffirmed its strong market position in the Duchenne Muscular Dystrophy (DMD) program following the reauthorization of the Rare Pediatric Disease Priority Review Voucher (PRV) Program, which allows for potential future PRV eligibility upon FDA approval of (Z)-endoxifen for DMD treatment [1][3] Group 1: Rare Pediatric Disease Designation - The Rare Pediatric Disease (RPD) designation is granted to drug candidates for serious or life-threatening diseases affecting individuals from birth to 18 years old, allowing for eligibility for a PRV upon FDA approval [2][4] - PRVs can be used for priority review of future applications or sold to other sponsors, with recent PRV sales ranging from $150 million to $200 million [2] Group 2: Company Statements and Insights - The renewal of the PRV program signals congressional recognition of the complexities and financial burdens in drug development, validating the potential of (Z)-endoxifen for DMD treatment [3] - Atossa's leadership emphasizes the urgent need for better treatment options for DMD beyond current therapies, highlighting (Z)-endoxifen's broader treatment approach [3] Group 3: Product and Market Potential - (Z)-endoxifen is a Selective Estrogen Receptor Modulator/Degrader (SERM/D) with a favorable safety profile and distinct pharmacology, currently not approved for any indication [6] - The company is advancing (Z)-endoxifen's development in both oncology and rare diseases, supported by a growing global intellectual property portfolio [7][8]
Zillow lets go of 200 employees in performance-related reductions at real estate company
GeekWire· 2026-01-30 18:17
Group 1 - The Seattle-based real estate company, Zillow, announced workforce reductions that account for approximately 2% of its total headcount [1]
Third Point拟对CoStar发起激进投资活动,或提名数名董事加入公司董事会
Ge Long Hui A P P· 2026-01-27 14:10
格隆汇1月27日|据路透,亿万富翁投资者Daniel Loeb的对冲基金Third Point正准备对房地产数据公司 CoStar Group发起激进投资活动。报道称,Third Point计划提名数名董事加入CoStar八人董事会,作为迫 使这家市值280亿美元公司进行变革的一部分。该对冲基金希望CoStar专注于其核心商业房地产业务, 同时关闭或出售近年来为与Zillow Group竞争而扩展的住宅业务。此外,Third Point还寻求削减成本, 包括CEO薪酬,并计划替换CoStar大部分董事会成员,以帮助提振公司股价。 ...